JOINT ACTION 3

Home  /  JOINT ACTION 3 (Page 2)

EUnetHTA is pleased to announce that the "Rapid Collaborative Review on the current role of antibody tests for novel coronavirus SARS-COV-2 in the management of the pandemic" is now available.  This is the first rapid review assessing health technologies for

This is the pharmaceutical Joint Assessment PTJA11 – Cefiderocol for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options. In April 2020, the European Commission granted marketing authorisation for Fetcroja® (cefiderocol) for the